Biomarkers in type 1 diabetes: Application to the clinical trial setting

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 21, Issue 4, 2014, Pages 287-292

  Tooley, James E ^a   Herold, Kevan C ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

biomarkers; clinical trials; type 1 diabetes

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CELL MARKER; AUTOANTIGEN; INTERLEUKIN 18;

CELL DEATH; CLINICAL TRIAL (TOPIC); DISEASE COURSE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; NONHUMAN; PANCREAS ISLET BETA CELL; PREDICTION; REVIEW; T LYMPHOCYTE; TREATMENT RESPONSE; FLOW CYTOMETRY; IMMUNOBLOTTING; METABOLISM; PATHOPHYSIOLOGY;

AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; INSULIN-SECRETING CELLS; INTERLEUKIN-18; T-LYMPHOCYTES;

EID: 84903820113     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000076     Document Type: Review

References (54)

1. Herold K, Vignali DA, Cooke A, Bluestone J. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol 2013; 13:243-256.
2. Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptiDe responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline iDentify a subgroup of responDers. Diabetes 2013; 62:3766-3774.
3. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3{gamma}1(Ala-Ala) results in improvement in CpeptiDe responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54:1763-1769. (Pubitemid 40770766)
4. Herold KC, Gitelman SE, Willi SM, et al. Teplizumab treatment may improve C-peptiDe responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2012; 56:391-400.
5. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692-1698. (Pubitemid 34547482)
6. Keymeulen B, VanDemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598-2608. (Pubitemid 41007846)
7. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised contr olled CD3-antibody trial in recent-onset type 1 diabetic patients Depends on their age and baseline residual beta cell mass. Diabetologia 2010; 53:614-623.
8. Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 378:412 -419.
9. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, Blymphocyte Depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143-2152.
10. Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378:487-497.
11. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine Deficiencies. Lancet 1974; 2:1279-1283.
12. Wenzlau JM, Juhl K, Yu L , et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007; 104:17040-17045. (Pubitemid 350210987)
13. Verge CF, Gianani R, Kawasaki E, et al. Prediction of type I diabetes in firstDegree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996; 45:926-933. (Pubitemid 26225509)
14. Yu M, Johnson JM, Tuohy VK. A pr edictable sequential Determinant spreading cascaDe invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptiDe-specific therapy after onset of clinical disease. J Exp Med 1996; 183:1777-1788.
15. Herold KC, Brooks-Worrell B, Palmer J, et al. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes 2009; 58:2588 -2595.
16. Turner R,Stratton I,Horton V,et al, UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid Decarboxylase for prediction of insulin requirement in type 2 diabetes.UK Prospective Diabete s Study Group,Lancet,1997,350,1288-1293. (Pubitemid 28036638)
17. Krischer JP, Cuthbertson DD, Yu L, et al. Screening strategies for the iDentification of multiple antibody-positive relatives of individuals with ty pe 1 diabetes. J Clin Endocrinol Metab 2003; 88:103-108. (Pubitemid 36115150)
18. Krischer JP, Schatz D, Riley WJ, et al. Insulin and islet cell autoantibodies as time-DepenDent covariates in the Development of insulin- DepenDent diabetes: a prospective study in relatives. J Clin Endocrinol Metab 1993; 77:743-749. (Pubitemid 23298659)
19. Achenbach P, Warncke K, Reiter J, et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004; 53:384-392. (Pubitemid 38174554)
20. Yu L, Robles DT, Abiru N, et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: eviDence for early Determination of subsequent diabetes. Proc Natl Acad Sci USA 2000; 97:1701-1706. (Pubitemid 30118506)
21. Barker JM, Barriga KJ, Yu L, et al. Prediction of autoantibody positivity and progression to type 1 diabete s: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004; 89:3896-3902. (Pubitemid 39071491)
22. Reijonen H, Daniels TL, Lernmark A, Nepom GT. GAD65-specific autoantibodies enhance the presentation of an immunodominant T-cell epitope from GAD65. Diabetes 2000; 49:1621-1626.
23. Coppieters KT, Dotta F, Amirian N, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 2012; 209:51-60.
24. Pinkse GG, Tysma OH, Bergen CA, et al. Autoreactive CD8 T cells associated with beta cell Destruction in type 1 diabetes. Proc Natl Acad Sci USA 2005; 102:18425-18430. (Pubitemid 43011242)
25. Roep BO, Stobbe I, Duinkerken G, et al. Auto-and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 1999; 48:484-490. (Pubitemid 29106860)
26. Skowera A, Ellis RJ, Va rela-Calvino R, et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 2008; 118:3390-3402.
27. Unger WW, Pearson T, Abreu JR, et al. Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell Destruction after engraftment into HLA-A2 transgenic NOD/scid/IL2RG null mice. PLoS One 2012; 7: e49213.
28. Arif S, Moore F, Marks K, et al. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokinemediated beta-cell Death. Diabetes 2011; 60:2112-2119.
29. Arif S, Tree TI, Astill TP, et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004; 113:451-463. (Pubitemid 38544189)
30. Miller BJ, Appel MC, O'Neil JJ, Wicker LS. Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J Immunol 1988; 140:52-58. (Pubitemid 18050680)
31. Viehmann Milam A, Maher SE, Gibson J, et al. A humanized mouse moDel of autoimmune insulitis. Diabetes 2014; 63:1712-1724. Injection of human CD4+ T cells pulsed with autoantigen-Derived peptiDes into HLA-DR4 transgenic immune Deficient mice resulted in insulitis and b cell Death.
32. Seyfert-Margolis V, Gisler TD, Asare AL, et al. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinDed controlled study. Diabetes 2006; 55:2588-2594. (Pubitemid 44871160)
33. Hadley D, Cheung RK, Becker DJ, et al. Large-scale prospective T cell function assays in shipped, unfrozen blood samples: experiences from the multicenter TRIGR trial. Clin Vaccine Immunol 2014; 21:203-211.
34. Mallone R, Mannering SI, Brooks-Worrell BM, et al. Isolation and preservation of peripheral blood mononuc lear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin Exp Immunol 2011; 163:33-49
35. Rigby M, DiMeglio L, RenDell M, et al. Targeting effector memory T cells with alefacept in new onset type 1 diabetes: 12 month results from the TIDAL study. Lancet Endocrinol Metab 2013; 1:284-294.
36. Herold KC, Pescovitz MD, McGee P, et al. Increased T cell proliferative responses to islet antigens iDentify clinical responDers to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol 2011; 187: 1998-2005.
37. Vendrame F,Pileggi A,Laughlin E,et al, Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, Despite immunosuppression, is associated with a utoantibodies and pathogenic autoreactive CD4 T-cells,Diabetes,2010,59,947-957.
38. Cernea S, Herold KC. Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clin Immunol 2010; 134:121-129.
39. Esplugues E, Huber S, Gagliani N, et al. Control of TH17 cells occurs in the small intestine. Nature 2011; 475:514-518.
40. Waldron-Lynch F, Henegariu O, Deng S, et al. Teplizumab induces human guttropic regulatory cells in humanized mice and patients. Sci Transl Med 2012; 4:118-12.
41. Moore A, Grimm J, Han B, Santamaria P. Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time. Diabetes 2004; 53:1459-1466. (Pubitemid 38697657)
42. Gaglia JL, Guimaraes AR, Hari singhani M, et al. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest 2011; 121:442-445.
43. Freeby M, Goland R, Ichise M, et al. VMAT2 quantitation by PET as a biomarker for beta-cell mass in health and disease. Diabetes Obes Metab 2008; 10 (Suppl 4):98-108.
44. Goland R, Freeby M, Parsey R, et al. 11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med 2009; 50:382-389.
45. Souza F, Simpson N, Raffo A, et al. Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat moDel. J Clin Invest 2006; 116:1506-1513.
46. Fagerholm V, Mikkola KK, Ishizu T, et a l. Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. J Nucl Med 2010; 51:1439-1446.
47. Greenbaum CJ, Beam CA, Boulware D, et al. Fall in C-peptiDe during first 2 years from diagnosis: eviDence of at least two distinct phases from composite TrialNet data. Diabetes 2012; 61:2066-2073.
48. Akirav EM, Lebastchi J, GalVan EM, et al. Detection of beta cell Death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci USA 2011; 108:19018-19023.
49. Lebastchi J, Deng S, Lebastchi AH, et al. Immune therapy and beta-cell Death in type 1 diabetes. Diabetes 2013; 62:1676-1680.
50. Erener S, Mojibian M, Fox JK, et al. Circulating miR-375 as a biomarker of beta-cell Death and diabetes in mice. Endocrinology 2013; 154:603-608.
51. Yu L, Herold K, Krause-Steinrauf H, et al. Rituximab selectively suppresses specific islet antibodies. Diabetes 2011; 60:2560-2565.
52. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type. Diabetes Care 2005; 28:1068-1076. (Pubitemid 40616615)
53. Wherrett DK, Bundy B, Becker DJ, et al. Antigen-bas ed therapy with glutamic acid Decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011; 378:319-327.
54. Axelsson S, Cheramy M, Akerman L, et al. Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial. Diabetes Care 2013; 36:3418-3424.